Question 17

Critically evaluate the use of veno-venous extracorporeal membrane oxygenation (V-V ECMO) for hypoxaemic respiratory failure in adults.
Your answer should include:
a) The criteria used to determine if a patient is a suitable candidate for V-V ECMO. (4 marks)
b) Advantages and disadvantages of V-V ECMO in this context. (3 marks)
c) The evidence for V-V ECMO in hypoxaemic respiratory failure. (3 marks)

[Click here to toggle visibility of the answers]

College answer

Syllabus topic/section:

2.1.4 Cardiovascular Intensive Care: Mechanical supports ECMO: L1


Discussion: 

Some candidates had a limited knowledge of VV ECMO and its physiological benefits and at times confused it with VA ECMO, particularly in part b).

Many candidates only provided the indications for VV ECMO in part a) and didn’t include the contraindications that would also determine a candidate's suitability for VV ECMO.
In part b) some candidates included broad statements like “prevents death or worsening organ failure” rather than describing the specific advantages of reduced ventilatory pressure to prevent further lung injury or reduction in hypoxia by returning fully oxygenated blood and clearing CO2.

The last part of the question was generally poorly answered, with few candidates demonstrating knowledge of the evidence or the controversies and little appreciation of the differing interpretations of the trials.

Discussion

Yes, ECMO might be described as a niche therapy available only in the Sandstone Centres of University-Affiliated Excellence, but the college does insist on producing high-quality fellows capable of working everywhere, and nobody would view them as a complete package if they cannot at least demonstrate some passing knowledge of this technology. The last time this came up, as Question 23 from the second paper of  2014 and Question 11 from the second paper of 2010, the pass rates were 43% and 19%, respectively. 

a) Criteria for suitability

  • Indications and favourable conditions
    • Severe hypoxia (eg. PF ratio >80)
    • Severe hypercapnia ( eg. CO2 > 60, pH >< 7.25)
    • High composite score (eg. Murray score > 3, as in the CESAR trial)
    • Ineffective conventional strategies (eg. no improvement from prone ventilation)
    • ARDS, CAP, asthma, aspiration, pulmonary contusions, alveolar haemorrhage, immunocompetent status
  • Contraindications and unfavourable conditions:
    • Age > 75, obesity (BMI > 45), poor vascular access
    • Prolonged injurious ventilation (eg. 7 days at Pplat 30)
    • Contraindications to anticoagulation, eg. intracranial haemorrhage or uncontrolled surgical bleeding
    • Poor prognosis for other reasons (eg. malignancy)
    • Multiorgan system failure (eg. in EOLIA trial, SAPSII > 90)

a) Advantages and disadvantages

The trainees answering this question would potentially be confused by the wording. "Advantages and disadvantages" of something usually means it is being compared to another option. What would that be in this case? Prone ventilation? Hypoxia and death? Hard to know. In this scenario, the safest stance to take would be "VV ECMO vs maximum conventional support including prone ventilation and/or inhaled pulmonary vasodilators", because that is the sort of position one would be forced into when ECMO is needed but not available.

Advantages

  • VV ECMO allows ventilation with protective volumes and pressures
  • This prevents further lung injury and allows healing
  • The modest pressures permitted by ECMO allow for adequate venous return and better haemodynamics, which in turn improves organ function 
  • The ability to remove CO2 removes the need for "permissive hypercapnia" which has adverse neurological and haemodynamic effects
  • The patient can be weaned from sedation and paralysis earlier, which decreases the risk of ICU-acquired weakness and delirium (plus the transition to spontaneous breathing is also faster)
  • The lack of dependence on high pressures and heavy-handed sedation makes cough safer and easier, which reduces the risk of pneumothorax and bronchopleural fistula (plus improves sputum clearance)
  • Awake patients supported on ECMO can participate in chest physiotherapy without breathlessness-related exercise intolerance

Disadvantages

  • ECMO in general is resource-expensive and carries a risk of vascular injuries, DVT, PE, pressure injuries, and anticoagulation-related bleeding risks (though this point is very generic, and it is unclear whether it would have gained any marks)
  • Unsuitable for patients with very high cardiac output (eg. young patients with respiratory sepsis and hyperdynamic circulation)
  • Unsuitable for patients with a very low cardiac output (eg. where the respiratory failure is complicated by cardiogenic shock)
  • The use of ultralow tidal volumes and modest pressures can lead to the development of atelectasis and pneumonia in previously viable lung
  • The risk of post-decannulation VTE from DVTs that formed in partially obstructed femoral veins can undo a lot of the positive gas exchange benefits of protective ventilation
  • Reduced mobility (or, increased risk of cannula dislodgement with mobility)
  • Recirculation can limit the efficiency of the circuit
  • Repositioning the patient becomes more dangerous, which leads to a reluctance to prone or regularly rotate the patient's position
  • Increased complexity of care leads to the increased propensity towards error, whereas conventional ventilation is simpler and less error-prone

c) The evidence for V-V ECMO in hypoxaemic respiratory failure:

There are only really two trials one can mention here:

  • CESAR (Peek et al, 2009)
    • ECMO within 7 days of initiating ventilation
    • n=180, in the UK.
    • No difference in mortality
    • 24% got randomised to ECMO but never received it.
  • EOLIA (Combes et al 2018)
    • ECMO within 7 days of initiating ventilation
    • n=249, mostly in France.
    • Difference in mortality 35% (ECMO) vs 46% (control) but not statistically significant, plus 28% crossed over to ECMO. 
  • ELSO registry: 58% survival in 36,865 cases in the last 5 years 
  • In short, the data are not sufficiently convincing to make a strong case for ECMO, but it remains the only option for patients failing conventional therapy (eg. prone ventilation) 
  • Unanswered questions include the optimal timing of ECMO (earlier = better?) and the ideal range of selection criteria.